254 related articles for article (PubMed ID: 1972347)
21. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
22. Mutant SV40 large T antigen as a therapeutic agent for HER-2/neu-overexpressing ovarian cancer.
Xing X; Matin A; Yu D; Xia W; Sorgi F; Huang L; Hung MC
Cancer Gene Ther; 1996; 3(3):168-74. PubMed ID: 8725881
[TBL] [Abstract][Full Text] [Related]
23. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.
Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R
Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
25. HER-2/neu oncogene expression and proliferation in breast cancers.
Bacus SS; Ruby SG; Weinberg DS; Chin D; Ortiz R; Bacus JW
Am J Pathol; 1990 Jul; 137(1):103-11. PubMed ID: 1973597
[TBL] [Abstract][Full Text] [Related]
26. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
Zhang Y; Yu D; Xia W; Hung MC
Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis.
Rubin SC; Finstad CL; Wong GY; Almadrones L; Plante M; Lloyd KO
Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):162-9. PubMed ID: 8093588
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
Wang Y; Zhang XR; Fu J; Tan W; Zhang W
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
[TBL] [Abstract][Full Text] [Related]
29. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
[TBL] [Abstract][Full Text] [Related]
30. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
31. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
32. [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas].
Fan QB; Bian ML; Huang SZ
Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):683-5, 710. PubMed ID: 7866905
[TBL] [Abstract][Full Text] [Related]
33. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.
Press MF; Hung G; Godolphin W; Slamon DJ
Cancer Res; 1994 May; 54(10):2771-7. PubMed ID: 7909495
[TBL] [Abstract][Full Text] [Related]
34. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
[TBL] [Abstract][Full Text] [Related]
35. HER-2/neu signal transduction in human breast and ovarian cancer.
Reese DM; Slamon DJ
Stem Cells; 1997; 15(1):1-8. PubMed ID: 9007217
[TBL] [Abstract][Full Text] [Related]
36. Growth factor expression in normal peritoneum of patients with gynecologic carcinoma.
Jennings TS; Dottino PR; Mandeli JP; Segna RA; Kelliher K; Cohen CJ
Gynecol Oncol; 1994 Nov; 55(2):190-7. PubMed ID: 7959283
[TBL] [Abstract][Full Text] [Related]
37. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
38. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.
Jimenez RE; Hussain M; Bianco FJ; Vaishampayan U; Tabazcka P; Sakr WA; Pontes JE; Wood DP; Grignon DJ
Clin Cancer Res; 2001 Aug; 7(8):2440-7. PubMed ID: 11489824
[TBL] [Abstract][Full Text] [Related]
39. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
Peredo R; Sastre G; Serrano J; Hunter Mellado R
Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
